Describe the role of radiotherapy in transplant-free salvage of relapsed Hodgkin lymphoma.
Identify patients for whom radiotherapy may be beneficial before or after chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory DLBCL.
Determine when radiotherapy alone should be used to treat lymphomas with an incomplete metabolic response to frontline systemic therapy.
